title: [Angiotensin II-induced hypertension chemotherapy of bone and soft-tissue sarcomas].
abstract: We treated 14 patients with high grade sarcomas by angiotensin II-induced hypertension chemotherapy. The chemotherapy protocol described by Rosen was selected according to histological classification of sarcomas (small cell sarcoma, spindle cell sarcoma, pleomorphic sarcoma). The level of angiotensin-induced hypertension was one and half times as high as blood pressure at rest. Induced hypertension was maintained for 30-60 minutes. In three cases of 5 primary osteosarcomas, induced hypertension resulted in the increase of tumor stain and/or vascularity angiographically, and chemotherapeutic effects were CR or PR. The six cases with soft-tissue sarcomas were 2 cases each of CR, PR, and NC. The decrease of relative tumor blood flow under the condition of angiotensin II-induced hypertension was detected in 5 cases of 6 soft-tissue sarcomas by 133Xe clearance method. In the case of rhabdomyosarcoma, the decrease of tumor stain and vascularity by induced hypertension was observed on angiogram. As the side effects accompanying induced hypertension, nausea and chest oppression were noted in 2 cases, respectively. In this study it was suggested that angiotensin II-induced hypertension chemotherapy was effective for osteosarcoma, but that it might be ineffective for soft-tissue sarcomas.
authors.affiliation: Dept. of Orthopedic Surgery, Kanazawa University, School of Medicine.
authors.forename: H
authors.initials: H
authors.lastname: Tsuchiya
authors.forename: K
authors.initials: K
authors.lastname: Tomita
authors.forename: M
authors.initials: M
authors.lastname: Sugihara
authors.forename: H
authors.initials: H
authors.lastname: Shimizu
authors.forename: H
authors.initials: H
authors.lastname: Yasutake
authors.forename: H
authors.initials: H
authors.lastname: Morishita
authors.forename: S
authors.initials: S
authors.lastname: Morikawa
authors.forename: M
authors.initials: M
authors.lastname: Ohno
authors.forename: H
authors.initials: H
authors.lastname: Bunko
authors.forename: M
authors.initials: M
authors.lastname: Seto
mesh_terms: D000293:Adolescent; D000328:Adult; D000804:Angiotensin II / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D001859:Bone Neoplasms / Q000188:drug therapy*; D002648:Child; D005260:Female; D018219:Histiocytoma, Benign Fibrous / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009442:Neurilemmoma / Q000188:drug therapy; D012516:Osteosarcoma / Q000188:drug therapy; D012208:Rhabdomyosarcoma / Q000188:drug therapy; D012509:Sarcoma / Q000188:drug therapy*; D012512:Sarcoma, Ewing / Q000188:drug therapy; D013584:Sarcoma, Synovial / Q000188:drug therapy; D012983:Soft Tissue Neoplasms / Q000188:drug therapy*
chemical_list: D000804:Angiotensin II